Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1

Status

Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 95Other hematologic neoplasm 51CNS 4Plasma cell 3Myeloid 2Dermatologic 2Head & Neck 1Genitourinary 1Classical hematology 1

Conditions

Multiple Myeloma 3Waldenstrom Macroglobulinemia 1Neoplasms, Plasma Cell 1

Interventions

Dexamethasone 262Lenalidomide 157daratumumab 135Bortezomib 113pomalidomide 89Calcium Dobesilate 86Cyclophosphamide 84carfilzomib 76Specimen Handling 46isatuximab 44fludarabine 43Biopsy 43belantamab mafodotin 41Magnetic Resonance Spectroscopy 38dexamethasone acetate 34dexamethasone 21-phosphate 34auricularum 33Melphalan 32talquetamab 29ixazomib 27iberdomide 27fludarabine phosphate 24selinexor 22elotuzumab 21Whole-Body Irradiation 17X-Rays 15venetoclax 14Mycophenolic Acid 13tocilizumab 12Stem Cell Transplantation 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
ibrutinib × Plasma cell × 1 year × Clear all
NCT07474961 2026-03-16

BLOOD-dose

Rigshospitalet, Denmark

Phase 4 Not yet recruiting
400 enrolled
LymphoidPlasma cell

Waldenstrom Macroglobulinemia, Multiple Myeloma

NCT03702725 2026-01-06

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Alliance Foundation Trials, LLC.

Phase 1 Completed
14 enrolled 15 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03015792 2025-08-17

Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant

Mayo Clinic

Phase 1 Terminated
18 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡